Pieta W. Bruggink-André de la Porte

TL;DR: Galectin-3 is a novel prognostic marker in patients with chronic HF that is independent of severity of HF, as assessed by NT-proBNP levels, and it may potentially be used in the management of such patients.

TL;DR: In this article, self-management interventions are widely implemented in the care for patients with heart failure (HF), however, trials show inconsistent results, and whether specific patient groups res...

TL;DR: Gal-3 is associated with left ventricular remodeling determined by serial echocardiography and predicts long-term mortality in patients with severe chronic HF and was a significant predictor of mortality after long- term follow-up.

TL;DR: In this article, the authors evaluated the effect of an intensive intervention at a heart failure clinic by a combination of a clinician and a cardiovascular nurse, both trained in heart failure, on the incidence of hospitalisation for worsening heart failure and/or all-cause mortality.

TL;DR: Although results were not consistent across outcomes, interventions comprising standardized training of interventionists, peer contact, log keeping, or goal-setting skills appeared less effective than interventions without these characteristics.